logo
Share SHARE
FONT-SIZE Plus   Neg

Pfizer's Rheumatoid Arthritis Drug Xeljanz Gets Approval In Japan

Pharmaceutical giant Pfizer Inc. (PFE) Monday said the Japanese Ministry of Health, Labor and Welfare has approved Xeljanz for the treatment of adults with rheumatoid arthritis or RA who have had an inadequate response to existing therapies. The company added saying the drug may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying antirheumatic drug, such as methotrexate.

Xeljanz is expected to be initially made available in Japan to medical institutions participating in an all-patient surveillance program. The drug will be commercially available in Japan after the National Health Insurance listing and will be co-promoted in Japan by Pfizer and Takeda Pharmaceutical Company Limited.

The approval of Xeljanz in Japan is supported by a multi-study, global clinical development program, which evaluated the drug in approximately 5,000 patients across various RA patient populations.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Google has been fined a hefty 2.42 billion euros or $2.7 billion by the European Commission for breaching EU antitrust rules. The Commission ruled that Google has abused its market dominance as a search engine by giving illegal advantage to its own comparison shopping service. Japanese game maker Nintendo announced its plans to launch Super NES Classic Edition, the standalone mini console, which will feature 21 pre-installed classic games. The Mini 16-Bit System is expected to hit the stores on September 29 for $79.99. Best Inc., a 23.4 percent owned by e-commerce major Alibaba Group, filed for Initial Public Offering in the U.S. According to the filing, Best expects to offer $750 million american depository shares.
comments powered by Disqus
Follow RTT